Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Consolidated Net Income: 2020-2024

Historic Consolidated Net Income for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$241.6 million.

  • NewAmsterdam Pharma Co N.V's Consolidated Net Income fell 332.54% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 11.15%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.54% down from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Consolidated Net Income stood at -$241.6 million for FY2024, which was down 36.54% from -$176.9 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Consolidated Net Income registered a high of -$6.6 million during FY2020, and its lowest value of -$241.6 million during FY2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Consolidated Net Income value was -$176.9 million (recorded in 2023), while the average stood at -$147.1 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Consolidated Net Income surged by 45.83% in 2022, and later plummeted by 681.73% in 2023.
  • NewAmsterdam Pharma Co N.V's Consolidated Net Income (Yearly) stood at -$6.6 million in 2020, then tumbled by 536.57% to -$41.8 million in 2021, then spiked by 45.83% to -$22.6 million in 2022, then slumped by 681.73% to -$176.9 million in 2023, then tumbled by 36.54% to -$241.6 million in 2024.